Date: Oct 29, 2013 Author: press release Source: Company Data (
click here to go to the source)
Columbus, Ohio - October 2013 - Leadscope® is pleased to announce the release of a new QSAR model E. Coli Sal 102 A-T Mutation (E. Coli) as part of the latest release of the Leadscope Model Applier Genetic Toxicity Statistical QSAR Suite. This model was developed under a Research Collaboration Agreement (RCA) between Leadscope and the U.S. Food ;amp Drug Administration (FDA).
This new E. Coli model along with the Leadscope Salmonella model will be used by the U. S. FDA in their testing under the ICH M7 Guidance for Impurities. The E. Coli model highlights alerting substructure and provides additional supportive evidence through the ability to perform analog searching of the Leadscope SAR Genetox Database.
Customers who license the Leadscope Model Applier - Genetic Toxicity Statistical QSAR Suite will receive the new E. Coli model at no additional cost.
Below is a summary of performance statistics for the E. Coli and Salmonella models:
The new version of the Model Applier provides a series of new reporting options that fully explain how the prediction was generated, including the REACH-compliant QPRF and QMRF report formats.
Leadscope will be exhibiting at the American College of Toxicology (ACT) Conference in San Antonio, Texas November 3-6, 2013. Please stop by our booth for a demonstration. If you are not attending the conference you may arrange for a demonstration of the new E. Coli or Salmonella models, by contacting Loftus Lucas at llucas@leadscope.com, Dr. Glenn Myatt at gmyatt@leadscope.com or Dr. Kevin Cross at kcross@leadscope.com. Or for further information, you may email Leadscope at info@leadscope.com.
